{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:03Z","timestamp":1786118823799,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>In testicular germ cell tumors (TGCTs), staging is a major determinant of disease-specific outcomes and dictates clinical management. The 8th edition of the American Joint Committee on Cancer (AJCC) staging manual recommends that tumor deposits in the spermatic cord that are discontinuous with the primary tumor be considered pathologic stage M1 (clinical stage [CS] III). This recommendation is controversial because, if patients do not show other metastases, it results in upstaging from CS I to III. This is relevant because CSI patients are candidates for active surveillance, whereas chemotherapy represents the standard treatment of CSIII patients. In this study, we describe the clinicopathologic findings and disease outcomes of TGCT patients presenting with discontinuous cord involvement no other concurrent metastases (ie, otherwise CS I). A total of 19 patients were assessed: 16 nonseminomas and 3 seminomas. When the focus of discontinuous spermatic cord invasion was excluded from staging, 10 tumors were pT3, 8 were pT2, and 1 was pT1. Adjuvant chemotherapy was given to 15 patients, 10 of whom developed disease recurrence (8 of them showing metastases in the retroperitoneum). None of the 4 patients kept on active surveillance showed evidence of recurrence at last follow-up, which is incompatible with the natural history of untreated CS III TGCTs. If the focus of discontinuous cord involvement was excluded from staging, these 4 cases were all pT2. Our data support that discontinuous cord invasion should not be considered pM1, since this practice may result in overtreatment of patients that could be kept on surveillance. We suggest staging these tumors as pT3(disc), considering this finding a risk factor for recurrence.<\/jats:p>","DOI":"10.1097\/pas.0000000000002552","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:00:07Z","timestamp":1776790807000},"page":"906-911","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Discontinuous Involvement of the Spermatic Cord by Germ Cell Tumors Should Not Be Considered Pathologic Stage M1"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"first","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)"},{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC)"},{"name":"Department of Pathology and Molecular Immunology, ICBAS - School of Medicine and Biomedical Sciences, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj","family":"Chinnam","sequence":"additional","affiliation":[{"name":"Department of Pathology, Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kvetoslava","family":"Michalova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Charles University, Faculty of Medicine, Plzen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita Salute San Raffaele, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur R.","family":"Sangoi","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar G.","family":"Peramato","sequence":"additional","affiliation":[{"name":"Autonomous University of Madrid, University Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana A.","family":"Morini","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rede D\u2019Or\/Sao Luiz Hospital, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Ricci","sequence":"additional","affiliation":[{"name":"Pathology Unit, DIAP-Dipartimento Interaziendale Anatomia Patologica di Bologna, Maggiore Hospital-AUSL Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Quiroga-Garza","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeboye O.","family":"Osunkoya","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Urology, Emory University, School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Gordetsky","sequence":"additional","affiliation":[{"name":"Vanderbilt University, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Flood","sequence":"additional","affiliation":[{"name":"University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad T.","family":"Idrees","sequence":"additional","affiliation":[{"name":"Department of Pathology, Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Masterson","sequence":"additional","affiliation":[{"name":"Department of Urology, Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Einhorn","sequence":"additional","affiliation":[{"name":"Department of Urology, Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Ulbright","sequence":"additional","affiliation":[{"name":"Department of Pathology, Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres M.","family":"Acosta","sequence":"additional","affiliation":[{"name":"Department of Pathology, Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"R1-20260715","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/ijc.21747","article-title":"Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality","volume":"118","author":"Bray","year":"2006","journal-title":"Int J Cancer"},{"key":"R2-20260715","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/157339406777934681","article-title":"Testicular germ cell tumors: a paradigm for the successful treatment of solid tumor stem cells","volume":"2","author":"Giuliano","year":"2006","journal-title":"Curr Cancer Ther Rev"},{"key":"R3-20260715","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00184714","article-title":"The impact of the \u201ccisplatin era\u201d of treatment on survival in testicular cancer","volume":"9","author":"Moul","year":"1991","journal-title":"World J Urol"},{"key":"R4-20260715","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2024.27122","article-title":"Testicular germ cell tumors: a review","volume":"333","author":"Singla","year":"2025","journal-title":"JAMA"},{"key":"R5-20260715","doi-asserted-by":"crossref","first-page":"e0225942","DOI":"10.1371\/journal.pone.0225942","article-title":"Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953\u20132015: a population-based prospective cohort study","volume":"14","author":"Kvammen","year":"2019","journal-title":"PLoS One"},{"key":"R6-20260715","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejso.2013.09.019","article-title":"Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis","volume":"40","author":"Gandaglia","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"R7-20260715","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1200\/JCO.21.00637","article-title":"Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort","volume":"39","author":"Hellesnes","year":"2021","journal-title":"J Clin Oncol"},{"key":"R8-20260715","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann Oncol"},{"key":"R9-20260715","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/14737140.2021.1932473","article-title":"How can we mitigate treatment-associated morbidity in patients with germ cell tumors?","volume":"21","author":"Bhanvadia","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"R10-20260715","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/1651-226X.2025.42281","article-title":"Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study","volume":"64","author":"Lindahl","year":"2025","journal-title":"Acta Oncol"},{"key":"R11-20260715","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eururo.2025.11.014","article-title":"Expert genitourinary pathology review of orchiectomy specimens should be mandatory for optimal management. Recommendations from the European Association of Urology guidelines panel on testicular cancer","volume":"89","author":"Lobo","year":"2026","journal-title":"Eur Urol"},{"key":"R12-20260715","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"R13-20260715","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"key":"R16-20260715","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1097\/PAS.0000000000000844","volume":"41","author":"Verrill","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R17-20260715","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41379-021-00912-9","article-title":"Testicular germ-cell tumors with spermatic cord involvement: a retrospective international multi-institutional experience","volume":"35","author":"Rodriguez Pena","year":"2022","journal-title":"Mod Pathol"},{"key":"R18-20260715","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/PAS.0000000000001008","article-title":"The significance of spermatic cord involvement by testicular germ cell tumors: should we be staging discontinuous invasion from involved lymphovascular spaces differently from direct extension?","volume":"42","author":"Sanfrancesco","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R19-20260715","doi-asserted-by":"crossref","first-page":"824","DOI":"10.5858\/arpa.2016-0226-OA","article-title":"The significance of lymphovascular invasion of the spermatic cord in the absence of cord soft tissue invasion","volume":"141","author":"McCleskey","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"R20-20260715","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/PAS.0000000000000917","article-title":"Do nonseminomatous germ cell tumors of the testis with lymphovascular invasion of the spermatic cord merit staging as pt3?","volume":"41","author":"Gordetsky","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R21-20260715","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euo.2020.11.004","article-title":"Utility of serum mir-371a-3p in predicting relapse on surveillance in patients with clinical stage I testicular germ cell cancer","volume":"4","author":"Lobo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R22-20260715","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41416-021-01643-z","article-title":"Detection of recurrences using serum mir-371a-3p during active surveillance in men with stage i testicular germ cell tumours","volume":"126","author":"Fankhauser","year":"2022","journal-title":"Br J Cancer"},{"key":"R23-20260715","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-23-0730","article-title":"Detection of recurrence through microrna-371a-3p serum levels in a follow-up of stage i testicular germ cell tumors in the drks-00019223 study","volume":"30","author":"Belge","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R24-20260715","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.2026.44.7_suppl.586","article-title":"Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906","volume":"44","author":"Tran","year":"2026","journal-title":"J Clin Oncol"},{"key":"R25-20260715","doi-asserted-by":"crossref","first-page":"114025","DOI":"10.1016\/j.ejca.2024.114025","article-title":"Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: a nationwide, population-based cohort study","volume":"202","author":"Wagner","year":"2024","journal-title":"Eur J Cancer"},{"key":"R26-20260715","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.23.00959","article-title":"Prognostic factors for relapse in patients with clinical stage I testicular seminoma: a nationwide, population-based cohort study","volume":"42","author":"Wagner","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:52:08Z","timestamp":1786035128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002552"}},"subtitle":["An International Multi-Institutional Study"],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002552","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2026-02-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}